Toronto, Ontario October 13, 2020 — QuestCap Inc. (“QuestCap” or the “Company”) (CSE:QSC; FRA:34C1) is pleased to announce that it will be uplisting to the NEO Exchange (“NEO”) effective October 15, 2020, concurrent with the NEO listing, the Company will transition to a single purpose company from an investment issuer, redeploying its assets and resources to be a single purpose medical company. QuestCap will continue to trade under the symbol “QSC” after listing on NEO Exchange.

By transitioning from an investment issuer to a single purpose company, QuestCap will be able to market the Company to investors in the United States effective October 15, 2020.

The NEO is considered a senior Canadian exchange akin to the TSX, however it offers issuers and investors enhanced liquidity, greater visibility, and lower fees. In conjunction with this uplisting, QuestCap has arranged for the delisting from the Canadian Stock Exchange (CSE), effective the close of trading on October 14, 2020. This transition is not expected to impact current investors ability to trade shares of QuestCap.

“As QuestCap grew its presence in the COVID-19 medical space, it became clear that the Company and its shareholders would be better served by a single purpose company, which would provide us with greater operating flexibility.” says Mr. Doug Sommerville, CEO of QuestCap. “We have worked closely with the NEO team over the previous months to make this transition and look forward to the improved trading liquidity and marketing options for the Company.”

About the NEO Exchange

NEO Exchange is a progressive stock exchange that brings together investors and capital raisers within a fair, efficient, and service-oriented environment. Fully operational since June 2015, NEO puts investors first and provides access to trading all Canadian-listed securities on a level playing field. The NEO Exchange lists senior companies and investment products seeking a stock exchange that enables investor trust, quality liquidity, and broad awareness including unfettered access to market data.

About QuestCap Inc.

QuestCap Inc. (CSE:QSC; FRA:34C1)  seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, QuestCap offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.

QuestCap has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space.  This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.

QuestCap’s primary focus is the sale of COVID-19 IgG/IgM antibody tests authorized by FDA under an EUA for use by authorized laboratories. This was achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments being handled through the online portal  www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.

For additional information, please contact:
Doug Sommerville, CEO
Doug.Sommerville@questcapinc.com
+1 416-301-5418

For investing inquiries please contact:
Evan Veryard
Evan.veryard@questcapinc.com

For US media enquires please contact:
Veronica Welch
veronica@vewprmedia.com
+1-508-643-8000

Cautionary Note Regarding Forward-looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, the proposed roll-out of testing sites; projected timelines for testing results; projected revenues from the testing; the pursuit by QuestCap of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.